Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
03/12/202108:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202108:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202101:25TipRanksWill Regeneron Face Troubles Against Omicron Variant?NASDAQ:REGNRegeneron Pharmaceuticals Inc
23/11/202118:55Dow Jones NewsNykode Therapeutics in Vaccine Deal With Regeneron Worth Up to $925 MillionNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/11/202122:25TipRanksAnalysts Are Bullish on These Healthcare Stocks: Field Trip Health (FTRP), Regeneron (REGN)NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/11/202108:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/11/202108:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
18/11/202108:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
18/11/202108:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
17/11/202108:15PR Newswire (US)Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/11/202123:00PR Newswire (US)Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive YearNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/11/202121:26TipRanksRegeneron Gets EU Approval for COVID-19 Antibody Cocktail, Announces $3B Share Repurchase ProgramNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/11/202108:53Dow Jones NewsRegeneron Announces $3 Billion Share Repurchase ProgramNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/11/202108:11PR Newswire (US)Regeneron Announces $3 Billion Share Repurchase ProgramNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/11/202102:20PR Newswire (US)Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/11/202103:57Dow Jones NewsRegeneron Gets CHMP Backing for Covid-19 CocktailNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/11/202103:43Dow Jones NewsEuropean Medicines Agency Recommends Ronapreve, Regkirona Covid-19 Treatments for ApprovalNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/11/202103:03PR Newswire (US)CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/11/202123:00PR Newswire (US)New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/11/202107:22Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/11/202101:00PR Newswire (US)Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and DisordersNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/202122:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/202122:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/202121:30PR Newswire (US)Regeneron Reports Third Quarter 2021 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/202107:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/202107:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/10/202115:59PR Newswire (US)Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex DiseaseNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/10/202121:39Dow Jones NewsRegeneron, Sanofi: Dupixent Hits Main Endpoints in Prurigo Nodularis TrialNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/10/202115:59PR Newswire (US)Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this DiseaseNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/10/202108:29PR Newswire (US)FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe AsthmaNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN